Why Is Abivax Stock Trading Higher On Monday?

1. ABVX presented ABTECT trial data at UEG Meeting, showing efficacy for obefazimod. 2. Obefazimod met FDA primary endpoint for clinical remission in ulcerative colitis. 3. 5.71% increase in ABVX stock noted after efficacy announcement. 4. No new safety signals reported for obefazimod, ensuring favorable risk assessment. 5. Robust improvement in clinical response observed across various patient subgroups.